Cargando…

Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium

Liver diseases are mostly triggered by oxidative stress and inflammation, leading to extracellular matrix overproduction and prone to develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver injury (LI) refers to various pathogenic factors leading to the destruction of stem cells t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jianxiong, Ye, Xietao, Yang, Songhong, Yu, Huan, Zhong, Lingyun, Gong, Qianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072898/
https://www.ncbi.nlm.nih.gov/pubmed/33912040
http://dx.doi.org/10.3389/fphar.2021.618846
_version_ 1783684011218960384
author Wu, Jianxiong
Ye, Xietao
Yang, Songhong
Yu, Huan
Zhong, Lingyun
Gong, Qianfeng
author_facet Wu, Jianxiong
Ye, Xietao
Yang, Songhong
Yu, Huan
Zhong, Lingyun
Gong, Qianfeng
author_sort Wu, Jianxiong
collection PubMed
description Liver diseases are mostly triggered by oxidative stress and inflammation, leading to extracellular matrix overproduction and prone to develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver injury (LI) refers to various pathogenic factors leading to the destruction of stem cells that then affect the liver’s normal function, causing a series of symptoms and abnormal liver function indicators. Citri Reticulatae Pericarpium (CRP) is one of the most commonly used traditional Chinese medicines; it contains flavonoids including hesperidin, nobiletin, and tangeretin. CRP has antibacterial, antioxidant, and antitumor effects that reduce cholesterol, prevent atherosclerosis and decrease LI. Here we analyzed the components of CRP and their targets of action in LI treatment and assessed the relationships between them using a systems pharmacology approach. Twenty-five active ingredients against LI were selected based on ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry results and databases. The drug targets and disease-related targets were predicted. The 117 common targets were used to construct a protein-protein interaction network. We identified 1719 gene ontology items in LI treatment, including 1,525 biological processes, 55 cellular components, and 139 molecular functions. These correlated with 49 Kyoto Encyclopedia of Genes and Genomes pathways. These findings suggest that CRP may counteract LI by affecting apoptotic, inflammatory, and energy metabolism modules. In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis. Naringenin significantly inhibited AKT1 phosphorylation, which in turn mediated activation of the phosphoinositide 3-kinase-Akt signaling pathways against LI. This study provides a reference for systematically exploring the mechanism of CRP’s anti-LI action and is also expands of the application of systems pharmacology in the study of traditional Chinese medicine.
format Online
Article
Text
id pubmed-8072898
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80728982021-04-27 Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium Wu, Jianxiong Ye, Xietao Yang, Songhong Yu, Huan Zhong, Lingyun Gong, Qianfeng Front Pharmacol Pharmacology Liver diseases are mostly triggered by oxidative stress and inflammation, leading to extracellular matrix overproduction and prone to develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Liver injury (LI) refers to various pathogenic factors leading to the destruction of stem cells that then affect the liver’s normal function, causing a series of symptoms and abnormal liver function indicators. Citri Reticulatae Pericarpium (CRP) is one of the most commonly used traditional Chinese medicines; it contains flavonoids including hesperidin, nobiletin, and tangeretin. CRP has antibacterial, antioxidant, and antitumor effects that reduce cholesterol, prevent atherosclerosis and decrease LI. Here we analyzed the components of CRP and their targets of action in LI treatment and assessed the relationships between them using a systems pharmacology approach. Twenty-five active ingredients against LI were selected based on ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry results and databases. The drug targets and disease-related targets were predicted. The 117 common targets were used to construct a protein-protein interaction network. We identified 1719 gene ontology items in LI treatment, including 1,525 biological processes, 55 cellular components, and 139 molecular functions. These correlated with 49 Kyoto Encyclopedia of Genes and Genomes pathways. These findings suggest that CRP may counteract LI by affecting apoptotic, inflammatory, and energy metabolism modules. In vitro experiments suggested that the mechanism may involve hesperidin and naringenin acting on CASP3, BAX, and BCL2 to affect the apoptosis pathway, attenuating liver fibrosis. Naringenin significantly inhibited AKT1 phosphorylation, which in turn mediated activation of the phosphoinositide 3-kinase-Akt signaling pathways against LI. This study provides a reference for systematically exploring the mechanism of CRP’s anti-LI action and is also expands of the application of systems pharmacology in the study of traditional Chinese medicine. Frontiers Media S.A. 2021-04-12 /pmc/articles/PMC8072898/ /pubmed/33912040 http://dx.doi.org/10.3389/fphar.2021.618846 Text en Copyright © 2021 Wu, Ye, Yang, Yu, Zhong and Gong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wu, Jianxiong
Ye, Xietao
Yang, Songhong
Yu, Huan
Zhong, Lingyun
Gong, Qianfeng
Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
title Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
title_full Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
title_fullStr Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
title_full_unstemmed Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
title_short Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium
title_sort systems pharmacology study of the anti-liver injury mechanism of citri reticulatae pericarpium
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072898/
https://www.ncbi.nlm.nih.gov/pubmed/33912040
http://dx.doi.org/10.3389/fphar.2021.618846
work_keys_str_mv AT wujianxiong systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium
AT yexietao systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium
AT yangsonghong systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium
AT yuhuan systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium
AT zhonglingyun systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium
AT gongqianfeng systemspharmacologystudyoftheantiliverinjurymechanismofcitrireticulataepericarpium